This Phase I/II randomized clinical trial investigates the safety, feasibility, and early regenerative potential of intra-articular administration of mesenchymal stem cell (MSC)-derived secretome combined with Plasma Rich in Growth Factors (PRGF) in patients with knee osteoarthritis (KOA). The study aims to assess whether this cell-free, biologically enriched therapeutic combination can reduce pain, improve joint function, and promote cartilage repair.
Diagnosed with primary OA in one or both knees based on American College of Rheumatology criteria
Grade I and II Arthritis
Joint pain ≥ 20mm measured by visual analogue scale
Age ranges from 30-55 years of age
• Secondary OA due to trauma, infection, rheumatoid arthritis, congenital disease or other inflammatory disorders of the knee
Diagnosed with a systemic autoimmune disorder, immunodeficiency or coagulation disorder
Had history of malignancy
History of allergy or allergic constitution
University of the Punjab
Lead sponsor
Centre of Excellence in Molecular Biology (CEMB), University of the Punjab, Lahore.
Collaborator